Hyperuricemia
📧 Sign up to get email alerts when something new happens for Hyperuricemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients [Phase 2]
Phase 2b trial evaluating AR882 for gout shows completed status; provides data on efficacy and safety in gout patients.
-
FDA approval · 2023-04-17FDA Approved: ULORIC — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ULORIC (febuxostat) submitted by Takeda Pharmaceuticals America, Inc. This action updates th…
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia [Phase 2]
Phase 2 trial evaluating ABP-671 for efficacy, safety, and pharmacokinetics in gout and hyperuricemia has completed.
-
FDA approval · 2023-03-15FDA Approved: ALLOPURINOL — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for Allopurinol from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. under ANDA204…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Uric Acid Lowering Trial in Youth Onset T2D [Phase 2]
Phase 2 clinical trial update investigating uric acid lowering in youth-onset type 2 diabetes with diabetic kidney disease and hyperuricemia…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-01-12FDA Approved: ALLOPURINOL — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for Allopurinol from Unichem Pharmaceuticals (USA), Inc., indicating approval of a supplement to the…
-
FDA approval · 2023-01-09FDA Approved: FEBUXOSTAT — Original Application (Zydus Lifesciences Limited)
FDA approved Zydus Lifesciences Limited's febuxostat Original Application, granting approval for a generic febuxostat product. Febuxostat is…
-
CLINICAL_TRIALS trial_result · 2022-08-24Clinical Trial Update: Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia [Phase 2]
Phase 2 clinical trial evaluating SHR4640 tablets in combination with febuxostat for primary gout and hyperuricemia.
-
FDA approval · 2022-08-08FDA Approved: ALLOPURINOL — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application from Gland Pharma Limited for Allopurinol, enabling the marketing of a generic Allopurinol product u…
-
FDA approval · 2022-08-04FDA Approved: ALLOPURINOL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for allopurinol submitted by Rising Pharma Holdings, Inc. This action authorizes a post-approval…
-
CLINICAL_TRIALS trial_result · 2022-08-01Clinical Trial Update: Pharmacogenetics of SGLT2 Inhibitors [Phase 4]
Phase 4 trial update on pharmacogenetics of SGLT2 inhibitors; terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: D-0120 Safety and PK/PD Study in China [Phase 1, Phase 2]
Phase 1/2 safety and PK/PD trial of D-0120 completed in China for hyperuricemia or gout.
-
FDA approval · 2022-03-28FDA Approved: FEBUXOSTAT — Original Application (Solco Healthcare US LLC)
FDA approved an original abbreviated new drug application for febuxostat submitted by Solco Healthcare US LLC.
-
FDA approval · 2022-03-07FDA Approved: ALLOPURINOL — Original Application (Harman Finochem Limited)
FDA approves the original application for Allopurinol from Harman Finochem Limited.
-
FDA approval · 2022-02-17FDA Approved: ALOPRIM — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for ALOPRIM (allopurinol) submitted by Mylan Institutional LLC.
-
CLINICAL_TRIALS trial_result · 2022-02-14Clinical Trial Update: Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid [Phase 2]
Phase 2 multi-dose safety and pharmacodynamic study of SEL-212/SEL-037 in symptomatic gout with hyperuricemia has completed with results pos…
-
FDA approval · 2022-01-26FDA Approved: ALLOPURINOL — Original Application (Gland Pharma Limited)
FDA approved the original application for allopurinol from Gland Pharma Limited, enabling a generic version in the United States.
-
FDA approval · 2021-12-07FDA Approved: FEBUXOSTAT — Original Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories, LLC's original application for febuxostat, a generic version of the gout and hyperuricemia medication.
-
CLINICAL_TRIALS trial_result · 2021-11-05Clinical Trial Update: Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients [Phase 2]
Phase 2 placebo-controlled trial evaluating safety, tolerability, PK, and PD of SAP-001 in gout patients with hyperuricemia completed.
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease [Phase 2]
Phase 2 trial update exploring uric acid reduction as a treatment for pediatric chronic kidney disease has been terminated.
-
CLINICAL_TRIALS trial_result · 2021-03-30Clinical Trial Update: The Diet Gout Trial [NA]
Clinical trial update for a diet-based intervention in gout and hyperuricemia, with completed status and results posted.
-
FDA approval · 2020-12-16FDA Approved: ALOPRIM — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for ALOPRIM (allopurinol) submitted by Mylan Institutional LLC.
-
CLINICAL_TRIALS trial_result · 2020-11-10Clinical Trial Update: Nutraceutical on Hyperuricemia [Phase 4]
Phase 4 clinical trial update for a nutraceutical addressing hyperuricemia has been completed.
-
FDA approval · 2020-10-22FDA Approved: FEBUXOSTAT — Original Application (DR REDDY'S LABORATORIES LIMITED)
FDA approved a generic febuxostat product from Dr. Reddy's Laboratories Limited via an Original Application (ANDA).
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients [Phase 4]
Phase 4 trial update on lowering hyperuricemia to assess cardiovascular outcomes in peritoneal dialysis patients.